Abstract:The m6A methyltransferase methyltransferase‐like 14 (METTL14) is downregulated in non‐small‐cell lung cancer (NSCLC), which can decrease the expression of LINC02747 through m6A modification and subsequently lower the malignant phenotype of NSCLC cells. Interestingly, we found that the low expression of METTL14 in NSCLC is due to the histone demethylase histone demethylase lysine‐specific histone demethylase 5B, which suppresses the transcription of METTL14 in a histone H3 lysine 4 tri‐methylation‐dependent manner. The correlation between the m6A modification mediated by METTL14 and histone modifications in NSCLC provides new insights into NSCLC therapy. Multiple epigenetic regulatory mechanisms exert critical roles in tumor development, and understanding the interactions and impact of diverse epigenetic modifications on gene expression in cancer is crucial for the development of precision medicine. We found that methyltransferase‐like 14 (METTL14) was significantly downregulated in non‐small‐cell lung cancer (NSCLC) tissues. Functional experiments demonstrated that overexpression of METTL14 inhibited the proliferation and migration of NSCLC cells both in vivo and in vitro, and the colorimetric m6A quantification assay also showed that knockdown of METTL14 notably reduced global m6A modification levels in NSCLC cells. By using the methylated‐RNA immunoprecipitation‐qPCR and dual‐luciferase reporter assays, we verified that long noncoding RNA LINC02747 was a target of METTL14 and was regulated by METTL14‐mediated m6A modification, and silencing LINC02747 inhibited the malignant progression of NSCLC by modulating the PI3K/Akt and CDK4/Cyclin D1 signaling pathway. Further studies revealed that overexpression of METTL14 promoted m6A methylation and accelerated the decay of LINC02747 mRNA via increased recognition of the "GAACU" binding site by YTHDC2. Additionally, histone demethylase lysine‐specific histone demethylase 5B (KDM5B) mediated the demethylation of histone H3 lysine 4 tri‐methylation (H3K4me3) in the METTL14 promoter region and repressed its transcription. In summary, KDM5B downregulated METTL14 expression at the transcriptional level in a H3K4me3‐dependent manner, while METTL14 modulated LINC02747 expression via m6A modification. Our results demonstrate a synergy of multiple mechanisms in regulating the malignant phenotype of NSCLC, revealing the complex regulation involved in the occurrence and development of cancer.

METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma

METTL14-mediated Lnc-LSG1 M6a Modification Inhibits Clear Cell Renal Cell Carcinoma Metastasis Via Regulating ESRP2 Ubiquitination

Methyltransferase‐like 14 Suppresses Growth and Metastasis of Renal Cell Carcinoma by Decreasing Long Noncoding RNA NEAT1

Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma

The m6A Methyltransferase METTL14-Mediated N6-Methyladenosine Modification of PTEN mRNA Inhibits Tumor Growth and Metastasis in Stomach Adenocarcinoma

METTL14-mediated N6-methyladenosine Modification of SOX4 Mrna Inhibits Tumor Metastasis in Colorectal Cancer

Functions, Mechanisms, and Therapeutic Implications of METTL14 in Human Cancer

Insights into roles of METTL14 in tumors

METTL14 Regulates CD8+T-cell Activation and Immune Responses to Anti‐pd‐1 Therapy in Lung Cancer

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers

Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer

Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma

The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma

Methyltransferase like‐14 suppresses growth and metastasis of non‐small‐cell lung cancer by decreasing LINC02747

M6A "Writer" Gene <i>METTL14</i>: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer

Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer

METTL3's role in cervical cancer development through m6A modification

P300/SP1 complex mediating elevated METTL1 regulates CDK14 mRNA stability via internal m7G modification in CRPC

METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST

RETRACTED: METTL14 Suppresses CRC Progression Via Regulating N6-Methyladenosine-Dependent Primary Mir-375 Processing